Physician profile
Brian A Jacobs
NPI 1437240694
$1,877.26
in general payments reported to CMS, 2019-2025
26 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $105 · 2023: $305 · 2024: $581 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $352.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $344.77 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $210.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $130.22 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $114.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.71 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $79.08 | 2019-2025 | Spravato |
| Abbott Laboratories | $75.82 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $65.62 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Insulet Corporation | $57.97 | 2023-2025 | Omnipod |
| Ethicon INC. | $41.85 | 2025 | Monarch Platform |
| Lilly USA, LLC | $38.24 | 2024-2025 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $31.40 | 2019 | |
| Amgen INC. | $30.28 | 2019 | |
| Radius Health, INC. | $23.48 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $23.03 | 2024 | Ingrezza |
| Seqirus USA INC | $22.43 | 2025 | Fluad, Flucelvax |
| Alnylam Pharmaceuticals INC. | $21.42 | 2025 | Givlaari |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.02 | 2024 | Rejoyn |
| Daiichi Sankyo INC. | $19.28 | 2024 | Injectafer |
| Dexcom, INC. | $16.27 | 2023 | Dexcom G6 Transmitter |
| Biogen, INC. | $16.02 | 2025 | Zurzuvae |
| Amarin Pharma, INC. | $15.07 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.60 | 2023 | Qelbree |
| Depuy Synthes Sales INC. | $13.32 | 2023 | Monovisc, Orthovisc |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.